Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells

BACKGROUND: Mesothelin (MSLN) is a classic tumor-associated antigen that is expressed in lung cancer and many other solid tumors. However, MSLN is also expressed in normal mesothelium which creates a significant risk of serious inflammation for MSLN-directed therapeutics. We have developed a dual-re...

Descripción completa

Detalles Bibliográficos
Autores principales: Tokatlian, Talar, Asuelime, Grace E, Mock, Jee-Young, DiAndreth, Breanna, Sharma, Shruti, Toledo Warshaviak, Dora, Daris, Mark E, Bolanos, Kristian, Luna, Breanna L, Naradikian, Martin S, Deshmukh, Kiran, Hamburger, Agnes E, Kamb, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804709/
https://www.ncbi.nlm.nih.gov/pubmed/35091455
http://dx.doi.org/10.1136/jitc-2021-003826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804709/
https://www.ncbi.nlm.nih.gov/pubmed/35091455
http://dx.doi.org/10.1136/jitc-2021-003826

Ejemplares similares